Don’t Overhype the New Health Care Venture
In an Axios column, Drew Altman dissects the many dimensions of the health cost problem and discusses why the Bezos-Buffett-Dimon initiative is unlikely to have much impact on the larger health cost problems the public and policymakers care about most.
Exit mobile version